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Abstract: Platelet interaction with collagens, via von Willebrand factor, is a potent trigger of
shear-dependent thrombus formation mediated by subsequent engagement of the signaling collagen
receptor glycoprotein (GP)VI, enforced by integrin α2β1. Protein tyrosine kinase Syk is central in
the GPVI-induced signaling pathway, leading to elevated cytosolic Ca2+. We aimed to determine
the Syk-mediated thrombogenic activity of several collagen peptides and (fibrillar) type I and III
collagens. High-shear perfusion of blood over microspots of these substances resulted in thrombus
formation, which was assessed by eight parameters and was indicative of platelet adhesion, activation,
aggregation, and contraction, which were affected by the Syk inhibitor PRT-060318. In platelet
suspensions, only collagen peptides containing the consensus GPVI-activating sequence (GPO)n and
Horm-type collagen evoked Syk-dependent Ca2+ rises. In whole blood under flow, Syk inhibition
suppressed platelet activation and aggregation parameters for the collagen peptides with or without
a (GPO)n sequence and for all of the collagens. Prediction models based on a regression analysis
indicated a mixed role of GPVI in thrombus formation on fibrillar collagens, which was abolished by
Syk inhibition. Together, these findings indicate that GPVI-dependent signaling through Syk supports
platelet activation in thrombus formation on collagen-like structures regardless of the presence of a
(GPO)n sequence.
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1. Introduction
Platelet interaction with subendothelial collagen is a crucial step in hemostasis or arterial
thrombosis after vascular injury or rupture of an atherosclerotic plaque, respectively [1,2]. In blood
flowing with high shear rates, the initial capture of platelets is mediated by the von Willebrand
factor (VWF), which avidly binds to collagens and is a ligand for the glycoprotein (GP) complex
GPIb–V–IX [3]. The two platelet collagen receptors integrin α2β1 and GPVI ensure stable platelet
adhesion and mediate platelet activation [4,5]. For over 20 years, GPVI has been recognized as the
central signaling collagen receptor on platelets [6,7].
Studies using genetically modified mice have shown that the (patho)physiological process of
arterial thrombus formation can be approximated using microfluidics devices, in which whole blood is
perfused over a collagen surface [8]. The collagen fibers immobilized in such devices, for instance those
applied as microspots, also bind plasma VWF and thus promote shear-dependent adhesion, activation,
and aggregation of platelets [3,9]. Previous results have revealed a strong interplay of GPIb-V-IX, GPVI,
and integrin α2β1 in the formation of large and stable multilayered thrombi in a way where the two
other receptors enforce the GPVI-induced activation of platelets [10,11]. Markedly, the thrombi that
formed on collagen fibers appeared to be heterogeneous in structure, with on the one hand patches
of aggregated platelets with activated integrin αIIbβ3 binding fibrinogen and CD62P expression via
α-granule secretion and on the other hand single procoagulant platelets, exposing phosphatidylserine
(PS), which is required for coagulation factor binding [12]. Particularly active in supporting thrombus
formation is the standard collagen preparation “Horm” (collagen-H), which is a fibrillar type I collagen
prepared in a proprietary process that is commonly used for diagnostics in the clinical laboratory.
Still unexplained is why other fibril-forming type I and III collagen preparations, also binding with
VWF, are less active in supporting thrombus formation under flow [9,13].
In previous years, a number of synthetic collagen-derived triple-helical peptides have been
identified that, similarly to collagen-H, bind to GPVI and/or integrin α2β1 and thus induce platelet
adhesion and activation in vitro [10]. Peptides containing the (GPO)n motif, in contrast to the
supposedly inactive (GPP)n motif, bind to GPVI, while peptides with the GFOGER motif act as strong
ligands for integrin α2β1 [14–16]. The prototypes of such triple-helical peptides are the cross-linked
collagen-related peptide (CRP-XL) with a (GPO)10 sequence, which hence acts as a potent GPVI
agonist, and the combined GFOGER–(GPO)n sequence, which binds to platelets via both receptors.
Subtle changes in the GFOGER sequence have been found to alter the affinity for α2β1. For instance,
the substitution of phenylalanine in GFOGER by alanine in GAOGER resulted in lower-affinity α2β1
binding and in diminished platelet adhesion under static conditions [17].
Platelet activation through GPVI [18–20], but not via GPIb-V-IX [21], relies on a potent protein
tyrosine kinase cascade, culminating in the activation of the tyrosine kinase Syk. This GPVI signaling
pathway involves phosphorylation of the Fc receptor γ-chain via Src-family kinases and construction of
a GPVI signalosome, in which Syk phosphorylates and activates phospholipase C (PLC)-γ2, causing a
rise in the central second messenger, Ca2+ [18,22–24]. However, the relative importance of this pathway
has not been investigated thus far in platelets interacting under flow with surface-immobilized collagen
peptides or fibrillar collagens.
In the present paper, we aimed to investigate the role of the GPVI-Syk pathway in thrombus
formation on collagen-like surfaces at a high shear rate. In particular, we assessed the subprocesses of
platelet adhesion, aggregation, and contraction as well as specific platelet activation responses. For this
purpose, we used a panel of collagens, collagen peptides, and collagen-H (with established GPVI
dependency) and the selective Syk inhibitor PRT-060318 (Syk-IN). The latter compound has recently
been used to specify Syk-dependent pathways in mouse platelets [21,25] and in human T cells [26].
As a direct readout of this signaling pathway, we also assessed Syk-dependent rises in cytosolic Ca2+.
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2. Results
2.1. GPVI-Dependent and Syk-Dependent Platelet Activation by Collagen Peptides
As a first estimation of the potency of distinct collagen peptides to act as ligands for platelet GPVI,
we examined their ability to stimulate PLCγ2-mediated rises in cytosolic Ca2+ using Fura-2-loaded
platelets. For a selective inhibitor of the GPVI pathway, we used the compound PRT-060318 (Syk-IN),
which was earlier used to identify Syk-dependent activation processes in platelets mediated by
GPVI [21,25] or CLEC2 [27]. The Syk-IN compound was found to phenocopy the effects of Syk depletion
on platelet responses in Syk−/− bone marrow chimeric mice [28]. Moreover, in human platelets, Syk-IN
selectively blocked the GPVI/Syk-dependent tyrosine phosphorylation and aggregation responses
induced by fibrin [29].
To confirm the selectivity of Syk-IN as an inhibitor of GPVI-induced responses of human platelets,
we monitored its effect (using 5 µM throughout) on the aggregation of platelets induced by CRP-XL,
thrombin, or stable ADP. This inhibitor caused the complete inhibition of aggregation only with the
GPVI agonist CRP-XL, whereas with thrombin or ADP it was ineffective (Figure S1A). This was in
agreement with earlier studies performed with mouse platelets [21,25]. Additional control experiments
with Fura-2-loaded human platelets indicated that Syk-IN did not suppress thrombin- or ADP-induced
Ca2+ rises (Figure S1B).
Table 1. Overview of composition of microspots (M1–9), platelet receptors implicated in thrombus
formation. Also indicated are the analyzed thrombus parameters (P1–8) from bright-field and
fluorescence microscopic images. Measured ranges and scaling for heatmap analysis were as
indicated. GP: Glycoprotein; PS: Phosphatidylserine; VWF-BP: von Willebrand factor binding peptide,
SAC: Surface area coverage, n.a., not assessed.
Microspot Platelet Receptors
GPVI α2β1 GPIb
M1 GFOGER-GPO + VWF-BP ++ ++ ++
M2 CRP-XL + VWF-BP ++ o ++
M3 GAOGER-GPO + VWF-BP ++ + ++
M4 GFOGER-GPP + VWF-BP (o)* ++ ++
M5 VWF-BP o o ++
M6 collagen-H (Horm type) ++ ++ ++
M7 collagen-I (human) n.a. n.a. ++
M8 monomeric collagen-I (human) n.a. n.a. ++
M9 collagen-III (human) n.a. n.a. ++
Parameter range scaling
Bright-Field Images
P1 platelet deposition (% SAC) 0–51.52 0–10
P2 platelet aggregate coverage (% SAC) 0–21.09 0–10
P3 thrombus morphological score 0–4.10 0–10
P4 thrombus multilayer score 0–2.60 0–10
P5 thrombus contraction score 0–2.94 0–10
Fluorescence Images
P6 PS exposure (% SAC) 0–13.91 0–10
P7 CD62P expression (% SAC) 0–46.71 0–10
P8 fibrinogen binding (% SAC) 0–28.33 0–10
* No GPVI-activating (GPP)n motif.
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Figure 1. Syk inhibition affecting platelet Ca2+ rises by collagen peptides with (GPO)n motif. Fura-2-
loaded platelets in 96-well plates were pre-incubated with Syk-IN (5 µM) or left untreated before 
stimulation with collagen peptide (M1-5, 10 µg/mL). Changes in [Ca2+]i were recorded over time per 
well-plate row by ratio fluorometry using a FlexStation 3. Peptides were injected into wells at 60 s 
(arrow) and reached platelets in a diffusion-limited way. (A) Calibrated [Ca2+]i traces recorded over 
600 s in the absence (black, control) or presence (gray) of a Syk inhibitor. Traces are representative of 
Figure 1. Syk inhibition affecting plat let Ca2+ rises by collag n p ptides with (GPO)n motif.
Fur -2-loaded platelets in 96-well plates were pre-incubated with Syk-IN (5 µ ) t untreated before
stimulation with collagen peptide (M1-5, 10 µg/mL). Changes in [Ca2+]i were recorded over time per
well-plate row by ratio fluorometry using a FlexStation 3. Peptides were injected into wells at 60 s
(arrow) and reached platel ts in a diffusion-limited way. (A) Calibrated [Ca2+]i traces recorded over
60 s in the absence (black, control) r inhibitor. Traces are representative
of three experiments. (B) Quantification for M1-5 of increased [Ca2+]i at 300 s (top graph) or 600 s
(bottom graph). Means ± SEM (n = 3). Paired Student’s t-tests; * p < 0.05, ** p < 0.01.
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Using Syk-IN, we then evaluated the role of Syk in platelet Ca2+ fluxes, which were induced
by several collagen peptides presumed to be GPVI-dependent or -independent. With three peptides
containing the consensus GPVI-activating motif (GPO)n, i.e., GFOGER-GPO (for convenience
designated as M1, see Table 1), CRP-XL (M2), and GAOGER-GPO (M3), we observed a potent
rise in [Ca2+]i, which was fully abolished in the presence of Syk-IN (Figure 1). Close examination of the
Ca2+ traces showed some differences between M1-3 at onset and the maximum value. The reason for
these differences was unclear, but they may have been linked to variations in the peptide conformation
or GPVI clustering capacity of the triple-helical peptide in question. On the other hand, two other
collagen peptides containing a (GPP)n motif instead of (GPO)n were unable to induce [Ca2+]i rises:
These were GFOGER-GPP (M4) and the VWF-binding peptide (M5). These Ca2+ traces were not
influenced by the presence of Syk-IN. Overall, these results indicated a high Syk dependency of the
platelet [Ca2+]i rises, which were induced by the (GPO)n-containing collagen peptides containing an
established GPVI-activating sequence.
2.2. GPVI- and Syk-Dependent Parameters of Thrombus Formation on Collagen Peptides
To assess how the five collagen peptides supported whole-blood thrombus formation, we applied
these as microspots (M1–5) in a microfluidic device, as described before [9]. The microspots were
supplemented with VWF-BP (peptide binding plasma VWF) to allow for GPIb-V-IX-mediated trapping
of platelets. Whole-blood perfusion was performed at a wall-shear rate of 1000 s−1. Through end-stage
(3.5 min) multicolor microscopic imaging, it was possible to analyze up to eight thrombus and platelet
characteristics: Overall platelet deposition (parameter P1, see Table 1); platelet aggregation (P2);
thrombus signature, i.e., morphology, multilayers, and contraction (P3-5); platelet procoagulant activity,
measured as PS exposure (P6); platelet activation parameter CD62P expression (P7); and fibrinogen
binding to activated integrin αIIbβ3 (P8).
Typically, the collagen peptides containing (GPO)n (M1–3) produced large thrombi with aggregated
platelets with high levels of activation markers, i.e., PS exposure, CD62P expression, and integrin
activation (Figure 2). In contrast, the non-GPVI-stimulating (GPP)n peptide GFOGER-GPP (M4)
caused the formation of smaller thrombi with residual CD62P expression and integrin activation,
but essentially no PS exposure. Quantification of the raw image data confirmed high parameter
values for all (GPO)n microspots from M1–3, indicating a strong ability to support thrombus formation
(Figure S2). Interestingly, when comparing the two GFOGER peptides with or without the GPVI-binding
motif (M1 or M4), the latter still induced residual platelet activation, in spite of lower thrombus signature
scores (P4-5) and limited PS exposure (P6). Furthermore, M1 (GFOGER), which had a supposedly
higher-affinity α2β1 binding motif than M3 (GAOGER), was less effective in promoting almost all
thrombus parameters (P1,2,3–5,7,8). The differences between microspots were visualized in a univariate
scaled heatmap of all parameters (Figure 3A). Together, the data suggested that the earlier distinction
made between high- and low-affinity α2β1 binding sites (established under static conditions [11,15])
became confusing in part when immobilized collagen peptides were exposed to platelets in flowing
whole blood. On the other hand, the apparent lack of both GPVI and α2β1 binding sites, as with M5,
resulted in almost no stable platelet adhesion and activation.
Parallel flow runs on all microspots from M1–5 were performed with blood samples pretreated
with Syk-IN (maximum effective dose of 20 µM) or DMSO vehicle. This resulted in marked reductions
in the majority of thrombus parameters (Figure 3A). A subtraction heatmap pinpointing only relevant
changes (p < 0.05) indicated that for M1–4, essentially all parameters except for P1 (platelet deposition)
were reduced by Syk inhibition (Figure 3B). Most drastic complete reductions were seen with PS
exposure (P6) on the “active” (GPO)n surfaces of M1–3. Surprisingly, Syk inhibition also affected
platelet activation at the supposedly non-GPVI (GPP)n surface of M4. The other microspot, M5,
was inactive in the absence of Syk-IN.
A summative plot was made indicating how individual (scaled) parameters were changed by Syk
inhibition across all microspots (Figure 3C). This revealed a complete reduction in P6 (PS exposure),
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along with strong reductions in P2 (aggregate coverage), P4 (thrombus multilayer), P5 (thrombus
contraction), and P8 (fibrinogen binding). Less affected were P3 (thrombus morphology) and P7
(CD62P expression).Int. J. Mol. Sci. 2019, 20, x 6 of 21 
 
 
Figure 2. Thrombus formation on immobilized collagen peptides with or without a (GPO)n motif. 
Whole blood was perfused over microspots M1 (GFOGER-GPO + VWF-BP), M2 (CRP-XL + VWF-BP), 
M3 (GAOGER-GPO + VWF-BP), M4 (GFOGER-GPP + VWF-BP), and M5 (VWF-BP), with assumed 
platelet adhesion via GPIb, GPVI, and/or integrin α2β1, as in Table 1. The wall-shear rate was 1000 s−1, 
with a perfusion time of 3.5 min. Representative bright-field microscopic images at the end stage are 
shown for an analysis of platelet deposition (parameter P1) and thrombus characteristics (P2–5). In 
addition, end-stage three-color fluorescence images for an analysis of PS exposure (AF568 annexin 
A5, P6), CD62P expression (AF647 α-CD62P, P7), and fibrinogen binding (FITC, P8) are shown. Scale 
bars represent 50 µm. 
Figure 2. Thrombus formation on immobilized collagen peptides with or without a (GPO)n motif.
Whole blood was perfused over microspots M1 (GFOGER-GPO + VWF-BP), M2 (CRP-XL + VWF-BP),
M3 (GAOGER-GPO + VWF-BP), M4 (GFOGER-GPP + VWF-BP), and M5 (VWF-BP), with assumed
platelet adhesion via GPIb, GPVI, and/or integrin α2β1, as in Table 1. The wall-shear rate was 1000
s−1, with a perfusion time of 3.5 min. Representative bright-field microscopic images at the end stage
are shown for an analysis of platelet deposition (parameter P1) and thrombus characteristics (P2–5).
In addition, end-stage three-color fluorescence images for an analysis of PS exposure (AF568 annexin
A5, P6), CD62P expression (AF647 α-CD62P, P7), and fibrinogen binding (FITC, P8) are shown. Scale
bars represent 50 µm.
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Figure 3. Effect of Syk inhibition on parameters of thrombus formation on immobilized collagen 
peptides. Blood samples pre-incubated with vehicle (Ctrl) or Syk-IN (20 µM) flowed over microspots 
M1–5, and the thrombi formed were imaged to obtain parameters P1–8, as in Figure 2. The effects of 
Syk-IN were assessed per blood sample, surface, and parameter. Mean values from individual blood 
samples (n = 5–7) were univariate-scaled to 0–10 per parameter across all surfaces M1–9. (A) Heatmap 
of scaled parameters, demonstrating the mean effects of Syk-IN. The rainbow color code indicates 
scaled values between 0 (blue) and 10 (red). (B) Subtraction heatmap representing the scaled effects 
of Syk-IN, filtered for relevant changes (p < 0.05, paired Student’s t-test per surface and parameter). 
The color code represents decreases (green) or increases (red) in comparison to control runs. (C) 
Cumulative inhibitory effect per parameter over all microspots, indicating relevant changes. 
2.3. GPVI-Induced and Syk-Dependent Platelet Activation by Different Collagens 
Subendothelial collagen types I and III are considered to be the major platelet-activating 
collagens in the vessel wall, acting via GPVI and α2β1 [30]. Equine standard collagen (collagen-H), 
likely a modified type I collagen, is the most commonly used collagen in studies of GPVI-induced 
platelet activation. This prompted us to compare four collagen preparations for their ability to 
support the GPVI-PLCγ2-Ca2+ activation pathway: The fibrous collagen-H (M6), human fibrillar 
Figure 3. Effect of Syk inhibition on parameters of thrombus formation on immobilized collagen
peptides. Blood samples pre-incubated with vehicle (Ctrl) or Syk-IN (20 µM) flowed over microspots
M1–5, and the thrombi formed were imaged to obtain parameters P1–8, as in Figure 2. The effects of
Syk-IN were assessed per blood sample, surface, and parameter. Mean values from individual blood
samples (n = 5–7) were univariate-scaled to 0–10 per parameter across all surfaces M1–9. (A) Heatmap
of scaled parameters, demonstrating the mean effects of Syk-IN. The rainbow color code indicates scaled
values between 0 (blue) and 10 (red). (B) Subtraction heatmap representing the scaled effects of Syk-IN,
filtered for relevant changes (p < 0.05, paired Student’s t-test per surface and parameter). The color
code represents decreases (green) or increases (red) in comparison to control runs. (C) Cumulative
inhibitory effect per parameter over all microspots, indicating relevant changes.
2.3. GPVI-Induced and Syk-Dependent Platelet Activation by Different Collagens
Subendothelial collagen types I and III are considered to be the major platelet-activating collagens
in the vessel wall, acting via GPVI and α2β1 [30]. Equine standard collagen (collagen-H), likely a
modified type I collagen, is the most commonly used collagen in studies of GPVI-induced platelet
activation. This prompted us to compare four collagen preparations for their ability to support
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the GPVI-PLCγ2-Ca2+ activation pathway: The fibrous collagen-H (M6), human fibrillar collagen-I
(M7), a degraded collagen-I (M8), and human fibrillar collagen-III (M9). Realizing that the very
high molecular mass of collagens results in a heterogeneous interaction with platelets in suspension,
we evaluated the [Ca2+]i rises induced by these collagens. Markedly, the four collagens (M6–9) evoked
a biphasic rise in [Ca2+]i, with an initial plateau level and a later second phase that was highest for
M7 and M9 (Figure 4A,B). In absolute levels, the rises in [Ca2+]i obtained with M6, 7, and 9 at a late
time point of 600 s were 2–3-fold lower than those seen with the (GPO)n-containing collagen peptides
(Figure 4 vs. Figure 1). This difference was likely due to the high molecular mass of the fibrillar-type
collagens, which slowed down the rate and extent of diffusion-limited interactions with platelets,
but it was also likely due to the higher density of the activation motif within the peptides. In addition,
it appeared that Syk inhibition completely suppressed the [Ca2+]i transients induced by the standard
collagen-H (M6), but it did not alter the transients of other collagens (Figure 4). In the presence of
indomethacin (10 µM, a thromboxane A2 pathway inhibitor), AR-C69931MX (10 µM, a P2Y12 receptor
inhibitor), or MRS2179 (100 µM, a P2Y1 receptor inhibitor), the rises in [Ca2+]i with collagens I–III were
suppressed by 15–28%, 31–32%, or 17–31%, respectively, in a nonredundant way (data not shown).
Taken together, this suggested the presence of a Syk-independent pathway for Ca2+ mobilization of
suspended natural collagens, which in part came from autocrine activation mechanisms.
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2.4. GPVI- and Syk-Dependent Platelet Responses in Thrombus Formation on Collagens
The same collagen preparations (M6–9) were also applied as microspots to test their ability to
support thrombus formation under flow. As indicated in Figure 5, collagen-H (M6) was the most potent
in provoking the formation of large aggregates of platelets with high PS exposure, granule secretion,
and fibrinogen binding, in agreement with the known high GPVI- and α2β1-activating potency of this
collagen when immobilized [9,11,12]. In comparison, the fibrillar type I (M7) and III (M9) collagens
formed only small aggregates of platelets with remaining secretion and fibrinogen binding, with M9
causing residual PS exposure (Figure 5). The degraded collagen-I (M8) caused mostly single-platelet
adhesion with incidental small-sized aggregates. The same information was obtained from the raw
mean values of individual parameters with these surfaces (Figure S3).Int. J. Mol. Sci. 2019, 20, x 10 of 21 
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exposure (AF568 a nexin A5, P6), CD62P expre sion (AF647 α-CD62P, P7), and fibrinogen binding
(FITC, P8) are shown. Scale bars represent 50 µm.
Heatmapping of the eight scaled parameter values confirmed that overall microspot
thrombogenicity decreased in the order of M6 > M7,9 > M8 (Figure 6A). Treatment of the blood with
Syk-IN left platelet deposition (P1) unchanged, but it decreased the thrombus signature and the platelet
activation parameters (P2–5; P7,8) for several collagens. A subtraction heatmap was built with a filter
for relevant changes (p < 0.05). For collagen-H (M6) as well as for fibrillar collagen-I and -III (M7,9),
it showed a reduction in almost all parameters except for P1 in the presence of Syk-IN (Figure 6B).
The parameters of platelet aggregation and contraction (P2,4,5) and platelet activation (P6 for M6, and
P7,8, for M7,9) were the most reduced.
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Figure 6. Effect of Syk inhibitio eters of thrombus formatio on immobilized collagen.
Whole blood pre-incubated with vehicle (Ctrl) -I (20 µM) was perfused over microspots M6–9,
and thrombus formation was imaged to obtain parameters P1–8, as in Figure 5. The effects of Syk-IN
were calculated per blood sample, surface, and parameter. Mean values for all blood samples (n = 5–7)
were univariate-scaled to 0–10 per parameter across all surfaces of M1–9. (A) A heatmap of the scaled
parameters showing the mean effects of Syk-IN. The rainbow color code gives scaled values between 0
(blue) and 10 (red). (B) A subtraction heatmap representing the scaled effects of Syk-IN, filtered for
relevant changes (p < 0.05, paired Student’s t-tests per surface and parameter). The color code represents
decreases (green) or increases (red) in comparison to control runs. (C) Cumulative inhibitory effect
over all microspots per parameter, indicating relevant changes from control runs.
To obtain an overall insight into the effect of Syk inhibition, a summative plot was again constructed
for each scaled parameter across all collagen microspots (Figure 6C). Importantly, this revealed a highly
similar effect of Syk inhibition, as previously seen for the collagen peptides. Summing up the values
for M6–9, we noticed a near-complete reduction in P6 (M6, PS exposure), along with strong reductions
in P2 (platelet aggregate coverage), P4 (thrombus multilayer), P5 (thrombus contraction), P7 (CD62P
expression), and P8 (fibrinogen binding) compared to vehicle-treated blood. Less affected by Syk
inhibition was P3 (thrombus morphology), while platelet adhesion (P1) was unchanged.
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In view of a possible role of GPVI also for platelet interaction with collagen type IV,
additional whole-blood flow runs (n = 3 donors) were performed with collagen-IV microspots.
Under control conditions, we noticed a pattern of thrombus formation resembling that of collagen-I
(M7) or collagen-III (M9). In the presence of Syk-IN, all parameters on collagen-IV were significantly
reduced (p < 0.01), with the exception of P2 and P6. Across all parameters, the median inhibitory effect
of Syk-IN for collagen-I, -III, and -IV was 87.8%, 88.0%, and 85.7%, respectively (data not shown).
Hence, we observed a similar extent of thrombus inhibition by Syk-IN for all of these fibrillar collagens.
2.5. Modeling of the Role of GPVI in Thrombus Formation on Various Collagens
We then applied a regression analysis to provide a systematic examination of the generated data
(M1–9), which consisted of 416 data points (52 mean control flow runs of 9 surfaces, 8 parameters),
to reveal the GPVI dependency of each surface. First, a partial least square (PLS) regression model
was generated for collagen peptides M1–3 (which had an assumed high GPVI dependency) and for
M4,5 (with supposedly no role for GPVI), after which the data from M6 (collagen-H) were entered
into the model. This analysis resulted in relevant components 1 and 2, explaining 68% and 15% of the
variation, respectively (Figure S4). A principal component plot indicated a tight cluster of flow runs
with M1–3,6. The data for M5 (negative component 1) and M4 (negative component 2) lay further
out in the model. This agreed with the large observed differences in (the parameters of) thrombus
formation on M4 and M5. The calculated beta matrix indicated that P2–6 contributed to the modeled
results to a similar extent.
Because of the separation of M4–5 parameters, the component 1 model was used for further
analysis. Prediction testing of the model showed near complete prediction accuracy for all surfaces,
except for M4 (because there was no component 2) (Table 2). The model was further used to predict
the role of GPVI in the remaining collagen surfaces, M7–9. For both fibrillar collagens (M7,9),
the prediction of GPVI dependency was mixed, while it was negative for the degraded collagen-I (M8).
Subsequently, we integrated into the model the second set of 416 data points of Syk-inhibited blood
samples (52 mean flow runs with Syk-IN for 9 surfaces, 8 parameters) to predict the absence of GPVI
activity. Markedly, across all surfaces, 51 out of 52 samples predicted a negative GPVI dependency,
wherein the only incorrectly predicted sample was just above the conventional 0.5 threshold value
for right prediction. Taken together, the constructed PLS model indicated, in addition to complete
GPVI-independency of all Syk-inhibited samples, no role of GPVI on surfaces M5 and M8.
Table 2. Modeled partial least square (PLS) analysis (based on component 1 principal component
analysis (PCA)) of range-scaled data for collagen peptides (M1–5) plus collagen-H (M6), with assumed
GPVI dependency. The ranges of prediction values are shown. Predicted accuracy is given by numbers
of mean flow runs per donor (control and Syk-IN). By default, a correct prediction was set at >0.5.
In addition, back-prediction of GPVI dependency of mean flow runs per donor for M7–9 is shown.
Prediction outcomes are given here in italics. The contributions of parameters to the prediction model
were in the order of P2–6 >> P1,7,8.
Microspot GPVI Dependency
Correctly Predicted
Range Ctrl Syk-IN
M1 positive 0.41–1.06 5/6 6/6
M2 positive 0.27–0.76 4/5 5/5
M3 positive 0.86–1.07 5/5 5/5
M4 negative 0.57–0.97 0/6 6/6
M5 negative 0.21–0.34 5/5 5/5
M6 positive 0.68–1.11 7/7 6/7
M7 mixed 0.44–0.85 5/7 7/7
M8 negative 0.13–0.41 0/5 5/5
M9 mixed 0.49–0.67 3/5 5/5
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3. Discussion
3.1. Collagen Peptides and GPVI-Dependent Platelet Activation
The data obtained indicated a clear separation between the effects of triple-helical collagen
peptides that contained the established GPVI recognition motif, (GPO)n [15], and peptides that had a
(GPP)n backbone instead. We found that the (GPO)n-containing collagen peptides (M1–3) (i) induced
high platelet Ca2+ rises under stasis, (ii) accomplished a fast build-up of thrombi with aggregated
and activated platelets under flow, and (iii) evoked platelet responses both under flow and static
conditions that were highly sensitive to the inhibition of Syk. Accordingly, these peptides provided
strong proof-of-principle evidence for potent stimulation of the GPVI-Syk-PLCγ2-Ca2+ pathway of
platelet activation.
Immobilized, the (GPO)n peptide CRP-XL (M2), lacking an α2β1 interaction motif, produced
smaller-sized thrombi (low parameter values in P2–6) than the other collagen peptides did, which was in
agreement with the known synergy between GPVI, integrin α2β1, and GPIb-V-IX receptors in thrombus
formation at a high shear rate [9–11]. Synergy of GPVI and α2β1 could also explain why peptides
containing the integrin-binding motif G(F/A)OGER evoked a faster Ca2+ signal when compared to
CRP-XL. Seemingly in contrast with its lower binding affinity to platelets under stasis [17], we observed
higher parameters of thrombus formation with GAOGER-GPO (M3) than with GFOGER-GPO (M1).
The explanation for this higher activity remains unclear.
In contrast, the (GPP)n-containing peptides GFOGER-GPP (M4) and VWF-BP (M5) did not evoke
detectable Ca2+ rises in platelets under stasis. Yet, when immobilized under flow, the integrin-binding
peptide GFOGER-GPP evoked low-parameter thrombus formation in terms of platelet activation and
aggregation, and this activity was again suppressed by Syk inhibition. This may have reflected weak
interaction of the (GPP)n motif with GPVI, reinforced by strong integrin-binding activity.
Jointly, these results pointed to a Syk-dependent role via GPVI in the support of thrombus
formation. This conclusion was supported by a reanalysis of earlier experiments, where effects of the
single-chain variable fragment antibody 10B12 were studied for the surfaces M1, M5, and M6 [16].
Markedly, image reanalysis providing the parameters P1,3–6 indicated a similar effect pattern of 10B12
as presently seen with Syk-IN (not shown).
3.2. Collagens and GPVI-Dependent Platelet Activation
Fibrillar type I and type III collagens are among the vessel wall components that most strongly
activate platelets [7,30]. Due to the structural complexity of multiple adjacent triple helices in
these collagens, little is known about how platelet receptors bind to the fibrils, although there is
evidence that the copresence of multiple binding sites in a collagen fiber enforces platelet adhesion
and activation [31,32]. Recent high-resolution microscopy has indicated that multiple copies of
GPVI dimerize and cluster along the fibers of such collagens, a process that is considered to enforce
GPVI-dependent platelet activation [33,34]. Previous sequence analysis has shown that both type I
and III collagens are made for up to 10% of GPO triplets, with α2β1 binding sequences present in both
cases, e.g., GFOGER in collagen-I and GAOGER in collagen-III [35].
Here, we compared the effects of preparations of human fibrillar collagen-I and collagen-III to
the standard collagen-H, i.e., a commercial equine type I-enriched preparation with fewer defined
supramolecular characteristics [36]. Markedly, added to suspended platelets, collagen-H (M6) was the
only collagen that induced Syk-dependent [Ca2+]i rises, whereas the other collagens (M7,9) induced
low [Ca2+]i rises that were insensitive to Syk inhibition. When microspotted, collagen-H triggered
the formation of large-size thrombi, with high parameters of platelet aggregation and activation,
i.e., responses that are known to be strongly GPVI-dependent [9] and that in the present setting were
consistently affected by Syk inhibition.
In addition, we tested a protease-treated, monomeric collagen-I preparation (M8), which appeared
to be inactive in supporting thrombus formation with no appreciable effect of Syk inhibition. This finding
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supports the notion that the fibrillar structure of immobilized collagens helps to expose receptor (GPVI)
binding sites upon stretching under flow conditions.
In comparison to collagen-H, the immobilized type I (M7) and type III (M9) collagens triggered
the formation of smaller thrombi with lower platelet activation parameters. Yet, for the fibrillar
collagens, the summed suppressive effects of Syk inhibition were remarkably similar to those seen
for collagen-H and the (GPO)n-containing collagen peptides. Given the similar abundance of GPO
triplets in both collagen-I and -III [15], these findings point to a limited role of GPVI-induced activation
under flow conditions. In agreement with such a role for GPVI, others have shown that immobilized
collagens can induce GPVI dimer clustering in adhered and spreading platelets [34]. In this setting,
immobilized collagen-III was found to be more effective in cluster formation than collagen-H or CRP-XL.
Furthermore, the inhibition of Syk did not abrogate the GPVI clustering. These findings suggest that
there is not a direct link between GPVI cluster formation and the strength of the GPVI-Syk-PLCγ2 signal.
However, under flow conditions, the additional involvement of VWF/GPIb-V-IX and integrin α2β1
interactions [13,16] might enforce the GPVI clustering pattern, but this still needs to be demonstrated.
3.3. Comparative Roles of GPVI and Syk in Platelet Activation
A remarkable finding was that Syk inhibition also affected parameters of thrombus formation
on surfaces that were considered to act independently of GPVI (i.e., GFOGER-GPP, M4) or with a
low GPVI dependency (collagen-I, M7; collagen-III, M9). As another approach to examine this, a PLS
model was constructed and used for principal component analysis. The PCA plots indicated a narrow
cluster for all high GPVI-activating surfaces (M1–3,6), with the data of M4,5 partly centering out.
A prediction of the role of GPVI for other surfaces gave a mixed outcome for the fibrillar collagens
(M7,9), whereas this was negative for the degraded collagen-I (M8). Importantly, the prediction model
revealed a consistent GPVI independence for the Syk-inhibited samples, regardless of the type of
microspot composition. Accordingly, this analysis supported the indication of low-level GPVI and Syk
activity at these weakly thrombogenic surfaces.
In recent years, evidence has accumulated on the role of GPVI signaling in platelets in (also)
contacting non collagen surfaces. For instance, GPVI dependency has been discovered for platelets
interacting with laminin [37], fibrin [29,38], or fibrinogen [39,40]. In this context, it is also likely
that for (GPP)n-containing surfaces, Syk-dependent platelet responses can be traced back to residual
GPVI activity. On the other hand, based on early studies, it cannot yet be excluded that (part of)
the Syk-dependent platelet responses in thrombus formation at “weaker” surfaces are mediated by
signaling via integrin αIIbβ3 [41–43], hence bypassing GPVI. This needs to be studied using specific
GPVI-inhibitory tools.
3.4. Conclusion
The present data revealed typical differences in the preparations of collagens or collagen peptides
if used in suspension with platelets or when immobilized as microspots and subjected to whole-blood
flow (Figure 7). Especially for the “weaker” fibrillar collagens, immobilization appeared to enhance the
signaling capability of GPVI, thus stimulating Syk-dependent platelet activation processes in thrombus
formation. Apart from changes in the (immobilized) collagen structure, other factors that may have
contributed to enhanced signaling capacity were the shear-dependent interaction of GPIb-V-IX with
collagen-bound VWF and the priming of platelet activation via integrin α2β1. These, and perhaps
also other receptor interactions with collagen fibers, may have ensured increased activation of the
GPVI-PLCγ2-Ca2+ pathway.
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Figure 7. Schematic platelet adhesion and activation by collagen under flow or in suspension.
(A) Under flow conditions, immobilized collagen-H interacted with VWF to capture platelets via
GPIb-V-IX and activate platelets via GPVI and integrin α2β1. Thrombi built up through the recruitment
of flowing platelets interacting with collagen/VWF-adhered platelets. Syk inhibition suppressed initial
platelet activation and platelet aggregate formation. (B) Collagen-H added to a suspension of platelets
transiently interacted with GPVI, resulting in Syk-dependent Ca2+ rises. Autocrine agonists stimulated
non-adhered platelets, responding through Syk-independent signals.
4. Materials and Methods
4.1. Materials
Collagen-related triple-helical peptides were synthesized as C-terminal amides and
purified by reverse-phase high-performance liquid chromatography [44,45]: H-GPC(GPO)3GFO
GER(GPO)3GPC-NH2 (GFOGER-GPO), H-GPC(GPP)5GFOGER(GPP)5GPC-NH2 (GFOGER-GP ),
cross-linked collagen-related (GPO)n peptide (CR -XL), GPC(GPO)3 AOGER(GPO)3GPC-NH2
(GAOGER-GPO), collage type III-derived VWF-binding peptide VWF-III (VWF-BP),
H-GPC( PP)5GPR QOGVMGFO(GPP)5GPC-NH2 [46]. Collagen-I Horm derived from equine tendon
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(collagen-H) was obtained from Nycomed (Hoofddorp, the Netherlands). Human placenta-derived
collagen-III (C4407), collagen-IV (C7521), and fibrillar collagen-I (C7774) came from Sigma-Aldrich
(Zwijndrecht, the Netherlands). The latter was used to prepare monomeric collagen-I through
pepsin treatment, as described in Reference [47]. The selective spleen tyrosine kinase (Syk)
inhibitor PRT-060318, 2-((1R,2S)-2-aminocyclohexylamino)-4-(m-tolylamino)pyrimidine-5-carboxamide
(Syk-IN), came from Bio-Connect (Huissen, the Netherlands). Used for fluorescence staining
were Alexa Fluor (AF)647-labeled antihuman CD62P mAb (304918, Biolegend, London, UK),
FITC-labeled fibrinogen (F0111, Dako, Amstelveen, the Netherlands), and AF568-labeled annexin A5
(A13202, ThermoFisher, Eindhoven, the Netherlands). Fura-2 acetoxymethyl ester and pluronic were
from Invitrogen (Carlsbad, CA, USA). Human α−thrombin was from Kordia (Leiden, the Netherlands).
Stable ADP (Me-S-ADP) and MRS-2179 were from Sigma-Aldrich. Other materials were from sources
described before [48].
4.2. Blood Isolation
Blood was obtained through venipuncture from healthy volunteers who had not received
antiplatelet medication for at least two weeks. All subjects gave their full informed consent according
to the Declaration of Helsinki. Studies were approved by the local Medical Ethics Committee.
Blood samples were collected into 3.2% trisodium citrate (Vacuette tubes, Greiner Bio-One, Alphen a/d
Rijn, the Netherlands). All subjects had platelet counts within the reference range, as measured with a
Sysmex XN-9000 analyzer (Sysmex, Cho-ku, Kobe, Japan).
4.3. Platelet Isolation and Loading with Fura-2
Platelet-rich plasma (PRP) was obtained from citrated blood through centrifugation at 870 g for 10
min. After the addition of 1:10 vol/vol acid citrate dextrose (ACD; 80 mM trisodium citrate, 183 mM
glucose, 52 mM citric acid), the isolated PRP was centrifuged at 2360 g for 2 min. Platelet pellets were
resuspended into HEPES buffer, pH 6.6 (10 mM HEPES, 136 mM NaCl, 2.7 mM KCl, 2 mM MgCl2,
5.5 mM glucose, and 0.1% bovine serum albumin). After the addition of apyrase (1 U/mL) and 1:15 v/v
ACD, another centrifugation step was performed to obtain washed platelets [48]. The final pellet was
resuspended in HEPES buffer, pH 7.45.
4.4. Light Transmission Aggregometry
The aggregation of washed platelets was measured by light transmission aggregometry,
as described in Reference [48], using an automated Chronolog aggregometer (Havertown, PA, USA).
The platelet aggregation rate was determined from maximal curve slopes (% transmission change per
min).
4.5. Whole-Blood Microfluidic Perfusion Over Microspots
Selected collagen-like peptides and collagens were microspotted on glass coverslips, essentially
as described before [9]. The coding of nine microspots (M1–9) is displayed in Table 1. In brief,
washed coverslips were coated with three different microspots, each containing a collagen (100 µg/mL)
or a combination of a collagen-like peptide (250 µg/mL) and VWF-BP (100 µg/mL). Coating doses
were chosen to obtain maximal platelet adhesion in flow assays [9]. The most active microspots were
always located downstream, thus preventing the cross-activation of platelets between microspots [9].
The coated coverslips were incubated overnight in a humid chamber at 4 ◦C and then blocked with
HEPES buffer (pH 7.45) containing 1% bovine serum albumin for 30 min before being mounted into
Maastricht microfluidic chambers.
For flow perfusion, 500 µL of citrated whole blood was pre-incubated for 10 min with either
vehicle (0.5% DMSO and 0.4 µg/mL pluronic, f.c.) or inhibitor PRT-060318 (Syk-IN, 20 µM in vehicle
solution, f.c.). After the addition of 40 µM PPACK and recalcification (3.75 mM MgCl2 and 7.5 mM
CaCl2), blood samples were perfused through microspot-containing flow chambers for 3.5 min at
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a wall-shear rate of 1000 s−1. After 2 min of staining for PS exposure (AF568-annexin A5), CD62P
expression (AF647 anti-CD62P mAb), and integrin αIIbβ3 activation (FITC fibrinogen), the residual
label was removed by postperfusion with HEPES buffer (pH 7.45) containing 2 mM CaCl2 and 1 U/mL
heparin. Vehicle controls were performed in duplicate, while samples containing Syk-IN were repeated
in triplicate using blood obtained from >5 different healthy donors.
4.6. Bright-Field and Fluorescence Microscopy
From each microspot, two bright-field images (during labeling) and three 3-colour fluorescence
images (after removing the label) were taken using an EVOS-FL microscope (Life Technologies,
Bleiswijk, the Netherlands) equipped with Cy5, RFP, and GFP LEDs; an Olympus UPLSAPO 60× oil
immersion objective; and a sensitive 1360 × 1024 pixel CCD camera [49]. A standardized image
analysis was performed using semiautomated scripts operated in Fiji (ImageJ), as described before [49].
Parameters extracted from bright-field images (P1–5), including thrombus signature scores (P3–5),
and parameters from fluorescence images (P6–8) are specified in Table 1.
4.7. Cytosolic Ca2+ Measurements
Washed human platelets (2 × 108/mL) were loaded with Fura-2 acetoxymethyl ester (3 µM) and
pluronic (0.4 µg/mL) through a 40-min incubation at room temperature. After another wash step and
resuspension of the platelets at the same concentration, changes in cytosolic [Ca2+]i were measured in
96-well plates using a FlexStation 3 (Molecular Devices, San Jose, CA, USA). In brief, 200 µL of platelet
suspension were pretreated with Syk-IN (5 µM) for 10 min or were left untreated. After the addition of
1 mM CaCl2, the Fura-2-loaded cells were stimulated by automated pipetting with one of the following
agonists (10 µg/mL) (for convenience, indicated as M1–9 (see Table 1)): GFOGER-GPO (M1), CRP-XL
(M2), GAOGER-GPO (M3), GFOGER-GPP (M4), VWF-BP (M5), collagen-H (M6), fibrillar collagen-I
(M7), monomeric collagen-I (M8), or collagen-III (M9).
Changes in Fura-2 fluorescence were measured over time at 37 ◦C by ratiometric fluorometry at
dual excitation wavelengths of 340 and 380 nm and an emission wavelength of 510 nm. The agonist
injection speed was set at 125 µL/s, resulting in complete, diffusion-limited mixing. Separate wells
contained Fura-2-loaded platelets that were lysed with 0.1% Triton-X-100 in the presence of either
1 mM CaCl2 or 9 mM EGTA/Tris for a determination of the Rmax and Rmin values, respectively [50].
After correction for background fluorescence, [Ca2+]i (as nM) was calculated from the ratio values [51].
Measurements were performed in duplicate wells and were completed within 2–3 h of preparation of
the cells.
4.8. Data Handling and Statistics
GraphPad Prism 8 was employed for statistical analysis. Heatmaps were generated with the
program R. For heatmap representation, all parameter values were univariate-normalized at a scale
of 0–10 [46]. Thrombus values of duplicate or triplicate flow runs from the same blood donor were
averaged to obtain one parameter set (vehicle or Syk-inhibited) per microspot and donor. Mean values
of control and inhibitor runs were then compared per blood sample using paired Student’s t-tests:
p-values below 0.05 were considered to be significant. For subtraction heatmaps, a standard filter of
p < 0.05 was set to visualize relevant effects.
4.9. Modeling to Predict GPVI Activity
Complete datasets (8 parameters, 9 surfaces) for flow runs of ≥5 donors were used to construct a
partial least square (PLS) model to predict GPVI dependency. First, range-scaled data for the collagen
peptide surfaces (M1–5) with known GPVI dependency were used to generate a PLS model, after which
collagen-H (M6) was then used to test the reliability of the model. A principal component analysis
(PCA) in 1- and 2-component mode was then applied, the predictions of which were supported by
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cross-validated analysis of Q2, defined as 1 - (PRESS/TSS) [52]. Subsequently, parameter sets of M7–9
were predicted for GPVI-dependency from the PLS model, as were parameters of M1–9 in the presence
of Syk-IN. By default, prediction values >0.5 were considered to be positive for GPVI dependency.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/11/
2788/s1. See separate file.
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